Virtu Financial LLC Acquires New Position in Cogent Biosciences, Inc. $COGT

Virtu Financial LLC acquired a new stake in Cogent Biosciences, Inc. (NASDAQ:COGT) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 37,619 shares of the technology company’s stock, valued at approximately $1,336,000.

A number of other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Cogent Biosciences by 48.4% during the 4th quarter. Vanguard Group Inc. now owns 11,514,326 shares of the technology company’s stock worth $408,989,000 after purchasing an additional 3,756,664 shares during the last quarter. Deerfield Management Company L.P. grew its position in shares of Cogent Biosciences by 242.9% in the third quarter. Deerfield Management Company L.P. now owns 9,053,118 shares of the technology company’s stock valued at $130,003,000 after purchasing an additional 6,412,903 shares in the last quarter. Fairmount Funds Management LLC increased its holdings in shares of Cogent Biosciences by 44.6% in the third quarter. Fairmount Funds Management LLC now owns 9,003,418 shares of the technology company’s stock valued at $129,289,000 after purchasing an additional 2,777,777 shares during the last quarter. RTW Investments LP increased its holdings in shares of Cogent Biosciences by 119.0% in the fourth quarter. RTW Investments LP now owns 7,592,241 shares of the technology company’s stock valued at $269,676,000 after purchasing an additional 4,124,755 shares during the last quarter. Finally, Commodore Capital LP lifted its position in Cogent Biosciences by 213.7% during the third quarter. Commodore Capital LP now owns 7,250,000 shares of the technology company’s stock worth $104,110,000 after buying an additional 4,938,836 shares in the last quarter.

Cogent Biosciences Stock Performance

Cogent Biosciences stock opened at $34.54 on Friday. The firm has a 50 day simple moving average of $34.43 and a 200-day simple moving average of $36.37. Cogent Biosciences, Inc. has a 1-year low of $6.92 and a 1-year high of $43.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 15.14 and a quick ratio of 15.14. The stock has a market cap of $5.90 billion, a price-to-earnings ratio of -15.92 and a beta of 0.34.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings results on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.53). On average, analysts expect that Cogent Biosciences, Inc. will post -2.26 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Wedbush reissued an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a research note on Friday, May 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a research note on Friday, April 10th. Jefferies Financial Group initiated coverage on Cogent Biosciences in a report on Monday, March 16th. They set a “buy” rating and a $55.00 price target on the stock. Finally, HC Wainwright boosted their price target on shares of Cogent Biosciences to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.73.

Cogent Biosciences Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.